Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - SARS-CoV-2 and cancer 1

1673MO - The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management


18 Sep 2020


Mini Oral - SARS-CoV-2 and cancer 1


COVID-19 and Cancer

Tumour Site




Annals of Oncology (2020) 31 (suppl_4): S934-S973. 10.1016/annonc/annonc289


A. LIÈVRE1, A. Turpin2, I.L. Ray-Coquard3, K. Le Malicot4, J. Thariat5, G. Ahle6, R. Mathieu7, V. Sebbagh8, D. Debieuvre9, A. Canellas10, M. Garcia-Larnicol11, R. Colle12, A. Hardy-Bessard13, L. Mansi14, J. Bourhis15, P. Gorphe16, R. Ursu17, A. IDBAIH Ahmed18, G. Zalcman19, O. Bouche20

Author affiliations

  • 1 Service Des Maladies De L'appareil Digestifcology, CHU Pontchaillou, 35000 - Rennes/FR
  • 2 Medical Oncology, Hopital Claude Huriez, 59037 - Lille/FR
  • 3 Department Of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon, 69008 - Lyon/FR
  • 4 Statistics, FFCD-, 21000 - Dijon/FR
  • 5 Radiotherapy, Centre François Baclesse, 14118 - Caen/FR
  • 6 Neurologist, Hôpitaux Civils de Colmar, 68000 - Colmar/FR
  • 7 Service D'urologie, CHU Pontchaillou, 35000 - Rennes/FR
  • 8 Hepato-gastroenterology Departement, Centre hospitalier de Compiegne, 60321 - Compiègne/FR
  • 9 Pneumology Department, Hopital Emile Muller GHRMSA, 68100 - Mulhouse/FR
  • 10 Pneumology Department, Hôpital TENON, 75000 - Paris/FR
  • 11 Responsable Médical, GERCOR, 75000 - Paris/FR
  • 12 Department Of Medical Oncology, Hôpital Saint-Antoine, 75000 - Paris/FR
  • 13 Department Of Medical Oncology, Hôpital Privé des Côtes d'Armor, 22190 - Plérin/FR
  • 14 Department Of Medical Oncology, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besançon/FR
  • 15 Radiation Oncology, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 16 Department Of Head And Neck Oncology, Gustave Roussy Institute, 94076 - Villejuif/FR
  • 17 Neurology Department, Hôpital Saint-Louis - APHP, 75000 - Paris/FR
  • 18 Neurology Department, Hopital de la Pitié Salpetrière, 75000 - Paris/FR
  • 19 Department Of Thoracic Oncology And Cic1425, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Université Paris-Diderot, 75018 - Paris/FR
  • 20 Gastroenterology And Gi Oncology, CHU de Reims - Hôpital Robert Debré, 51092 - Reims/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1673MO


The novel COVID-19 outbreak spread rapidly around the world. Cancer patients (pts) consist of a highly vulnerable group due to underlying malignancy and/or treatment-induced immunosuppression. A high mortality rate from COVID-19 in cancer pts was previously reported. France is the fourth most affected country, with more than 150,000 infected individuals and over 28,000 deaths. GCO-002 CACOVID-19 study is a large French nationwide cohort of COVID-19 pts with solid tumors with the aim to identify risk factors of COVID-19 severity and evaluate impact on cancer treatment.


Bispective multicenter cohort set up by the French Cooperative Groups in solid cancers: ANOCEF-IGCNO (CNS tumors), ARCAGY-GINECO (gynecological and breast cancers), FFCD (digestive cancers), GERCOR (digestive and other solid cancers), GORTEC/intergroupe ORL (head and neck cancers (H&N), and IFCT (thoracic cancers). French pts with solid cancers and COVID-19 diagnosed since 1 March 2020 were accrued. Exclusion criteria: pts treated curatively > 5 years ago.


From 6 April to 15 May 2020, 835 pts from 136 institutions (general hospitals 35%, university hospitals 35%, private centers 25%, cancer centers 5%) were registered. Men: 61%, median age: 69 years (20-100). Digestive cancers: 43% (16%/9% colorectal/pancreatic cancers), lung cancers: 22%, gynecological: 14%, (9% breast cancers), H&N: 10%, CNS: 4%, urologic cancers: 3%. Advanced or metastatic: 61%. Within 3 months before COVID-19 diagnosis, 69% of pts received a systemic anticancer treatment (chemotherapy, targeted or immune therapy) and 22% a local therapy (surgery, radiotherapy or local destruction). Diagnosis of COVID-19 was confirmed by RT-PCR, CT-scan or both in 91% or serology in 1.4%. COVID was treated in the same oncological center in 78%. During the follow-up period (mean 14 days), 208 (25%) pts died, including 173 (21%) COVID-19 related deaths.


This first nationwide study of cancer pts with COVID-19 from France reports a high mortality rate. Updated and detailed data on anti-cancer treatments, risk factors of severe and fatal COVID-19 and impact of COVID-19 on cancer management will be presented.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Fédération Francophone de Cancérologie Digestive.


Has not received any funding.


A. Lièvre: Honoraria (self), Advisory/Consultancy: AAA; Amgen, Pierre Fabre; Sandoz; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Bayer; Novartis; Honoraria (self): Celgene; HalioDx; Lilly; Honoraria (self), Travel/Accommodation/Expenses: BMS; Roche; Honoraria (self), Research grant/Funding (self): Incyte; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Merck; Servier; Research grant/Funding (self): Integragen; Travel/Accommodation/Expenses: AAA; Pfizer. A. Turpin: Honoraria (self): Servier; Advisory/Consultancy: Mylan; Merck Serono; Amgen; Travel/Accommodation/Expenses: Merck; Sanofi; Pfizer; AstraZeneca. I.L. Ray-Coquard: Honoraria (self), Advisory/Consultancy: Abbvie; Agenus; Advaxis; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): BMS; MSD; Honoraria (self), Advisory/Consultancy: PharmaMar; Genmab; Pfizer; Deciphera; Mersena; Amgen; Tesaro; Clovis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: GSK; Non-remunerated activity/ies: GINECO; ENGOT; GCIG; European community; ESMO; ASCO; ESGO; IGSC; Inca; Swiss and German Health Authorities; Italian Health Authority; Belgium Health Authority. J. Thariat: Honoraria (self): BMS; Honoraria (institution), Travel/Accommodation/Expenses, Full/Part-time employment: Centre François Baclesse; Leadership role: President of the French Head and Neck Intergroup, GORTEC secretary; Non-remunerated activity/ies: Director of Easy-CRF society; Research grant/Funding (institution): Nanobiotix. G. Ahle: Travel/Accommodation/Expenses: Abbvie; Biogen; Novartis; Roche; Sanofi; Non-remunerated activity/ies: ANOCEF; NENO; AlSacEP. R. Mathieu: Honoraria (self), Research grant/Funding (self): Astellas; Honoraria (self): AstraZeneca; Ferring; Ipsen; Janssen; MSD; Pfizer; Sanofi; Takeda. D. Debieuvre: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Roche; Novartis; BMS; MSD; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Research grant/Funding (institution): Chugaï; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Boerhinger-Ingelheim; Research grant/Funding (institution): Chiesi; Sandoz; Takeda; GSK; Research grant/Funding (self): Lilly. A. Canellas: Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Oxyvie; LVL Medical; Boerhinger Ingelheim. A-C. Hardy-Bessard: Advisory/Consultancy: Clovis; Novartis; Roche; MSD; AstraZeneca; GSK. L. Mansi: Honoraria (institution), Advisory/Consultancy: Sandoz; Advisory/Consultancy: Roche; Eisai; Pfizer; Novartis; Speaker Bureau/Expert testimony: Exact Sciences; Travel/Accommodation/Expenses: Lilly. P. Gorphe: Honoraria (self): Intuitive Surgical; Non-remunerated activity/ies: Chair, scientific board, French Head and Neck Intergroup; Research grant/Funding (institution): MSD. A. IDBAIH Ahmed: Research grant/Funding (institution): Transgene; Sanofi; Air Liquide; Travel/Accommodation/Expenses: Carthera; Leo Pharma. G. Zalcman: Honoraria (self), Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (institution): Takeda; Travel/Accommodation/Expenses: Pfizer; AbbVie; MSD. O. Bouche: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Merck KgaA; Bayer; AstraZeneca; Grunenthal; MSD; Honoraria (self), Speaker Bureau/Expert testimony: Amgen; Pierre Fabre;Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Servier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.